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A. Summary (english, german) 
ADULT NEUROGENESIS IN TRANSGENIC ANIMAL MODELS OF 
DYT1 PRIMARY TORSION DYSTONIA 
Primary torsion dystonia is a hereditary movement disorder characterized by generalized, 
sustained, involuntary muscle contractions with an underlying three-base-pair deletion in the 
DYT1 gene coding for torsinA. The precise role of torsinA and the effect of its mutated form 
remain unclear to date, but its functions have been linked to chaperones, secretory cellular 
mechanisms, dopaminergic metabolism and to plasticity and synaptogenesis. Adult neuro-
genesis is the generation of new neurons throughout adulthood restricted to the two neurogen-
ic zones of the adult mammalian brain, the dentate gyrus of the hippocampus and the subven-
tricular zone of the lateral ventricles. It is affected by many acute and degenerative diseases of 
the central nervous system and might be responsible for some of their symptoms. Moreover, it 
is regulated by striatal dopamine levels and provides a form of cellular neural plasticity. 
We investigated the effect of torsinA on adult neurogenesis in two previously described trans-
genic mouse models of DYT1-related torsion dystonia, one group overexpressing human 
wildtype torsinA and the other human mutant torsinA. Animals underwent a standard BrdU 
injection paradigm and were examined immunohistochemically 28 days later. We found that 
transgenic torsinA was not expressed within neural precursor cells in both groups. Prolifera-
tion within the neurogenic zones and survival of the newly generated cells, as detected by the 
numbers of PCNA- and BrdU-positive cells, respectively, did not differ from control animals. 
In addition, there were no signs of striatal neurogenesis or neuronal migration into the stria-
tum. 
Hence, the transgene has neither an endogenous nor an exogenous influence on adult neural 
stem and progenitor cells in these in vivo models and adult neurogenesis is not altered in this 
model. However, more studies are needed to further rule out a possible function of torsinA in 
embryonic neurogenesis. 
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DIE ADULTE NEUROGENESE IN TRANSGENEN TIERMODELLEN DER 
PRIMÄREN DYT1-TORSIONSDYSTONIE 
Die primäre Torsionsdystonie ist eine erbliche Bewegungsstörung, bei der es aufgrund einer 
3-Basenpaar-Deletion im DYT1-Gen zu generalisierten, unwillkürlichen und anhaltenden 
Muskelkontraktionen kommt. Die exakte Rolle des Genprodukts TorsinA und dessen mutier-
ter Form ist noch immer unbekannt, aber dessen Funktion wurde mit Chaperonen, sekretori-
schen Zellmechanismen, dem Dopaminstoffwechsel und mit Plastizität und Synaptogenese in 
Verbindung gebracht. Die adulte Neurogenese ist die Neubildung von Neuronen während 
des Erwachsenenalters und ist physiologischerweise begrenzt auf zwei neurogene Zonen des 
adulten Säugergehirns: den Gyrus dentatus des Hippokampus und die Subventrikulärzone der 
Seitenventrikel. Die adulte Neurogenese ist bei vielen akuten und degenerativen Erkrankun-
gen des zentralen Nervensystems verändert und trägt möglicherweise zu einem Teil der 
Symptome bei. Außerdem wird sie durch die Dopaminspiegel moduliert und stellt eine Form 
zellulärer neuraler Plastizität dar. 
In dieser Arbeit wurde der Effekt von TorsinA auf die adulte Neurogenese in zwei bereits 
charakterisierten transgenen Mausmodellen von DYT1-Torsionsdystonie untersucht. In der 
einen Gruppe war die Wildtyp-Form von TorsinA überexprimiert, in der anderen die mutierte 
Form. Die Tiere erhielten wiederholte BrdU-Injektionen und wurden 28 Tage später immun-
histochemisch untersucht. In keiner der beiden Gruppen war transgenes TorsinA in neuralen 
Vorläuferzellen exprimiert. Die Proliferation in den neurogenen Zonen und das Überleben der 
neugebildeten Zellen wurden durch Zählung PCNA- und BrdU-positiver Zellen ermittelt. 
Diese zeigten keine Unterschiede zwischen transgenen und Kontroll-Gruppen. Zudem zeigte 
sich kein Hinweis auf striatale Neurogenese oder neuronale Wanderung in das Striatum. 
Daher hat das Transgen in diesen in-vivo-Modellen weder einen endogenen noch einen exo-
genen Einfluss auf adulte neurale Stamm- und Progenitorzellen und führt auch zu keiner Ver-
änderung der adulten Neurogenese. Dennoch sind weitere Untersuchungen nötig, um eine 
Auswirkung von TorsinA insbesondere auf die embryonale Neurogenese auszuschließen. 
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B. Introduction 
 
1. Primary torsion dystonia 
History: Dystonias are a group of movement disorders characterized by sustained involuntary 
contractions of one or more groups of muscles resulting in abnormal body postures. A first 
clear description of dystonia dates back to 1911 when the neurologist Hermann Oppenheim 
observed a variety of hypertonic muscles while most of the other muscles were hypotonic at 
the same time in several young boys (Oppenheim 1911). He termed this disease “dystonia 
musculorum deformans” (Fahn 1988; Grundmann 2005). 
 
Clinical features and classifications: Dystonias comprise a clinically and genetically hetere-
ogenous group of movement disorders characterized by sustained muscle contractions affect-
ing one or more sites of the body, frequently causing twisting and repetitive movements or 
abnormal postures due to central nervous dysfunction (Fahn et al. 1998). The term “dystonia” 
can serve as description for the clinical symptom of these sustained muscle contractions. In 
addition, it can refer to the clinical syndrome when dystonia is part of another underlying neu-
rological disorder (i.e. secondary or symptomatic dystonia) or refer to an own entity (i.e. pri-
mary or idiopathic dystonia) when the symptom dystonia is the primary and sole abnormality 
attributable to the condition. 
Thus, primary dystonia patients show no other phenotypic abnormality than dystonic move-
ments and for these, no known cause apart from genetic mutations can be found (Tarsy and 
Simon 2006). Secondary dystonias, on the other hand, have a spectrum of different known 
causes including neurodegenerative diseases like Parkinson’s disease (PD) or Huntington’s 
disease (HD) and including drug-induced dystonia as a side-effect of antipsychotics. In a third 
category, dystonia-plus syndromes have been distinguished from secondary dystonias because 
they show other neurological signs in addition to dystonia, e.g. parkinsonism in dopa-
responsive dystonia. 
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Dystonia as a 
syndrome 
Etiology Age 
at onset 
Topographic 
Distribution 
Topographic 
Progression 
Prevalence 
per 100.000 
as an own 
entity primary 
hereditary 
(DYT1, 2, 
4, 6, 7, 13, 
16) 
infantile 
generalized 
frequent / 
fast 
3 
juvenile 
hemidystonia 
sporadic 
adult rare / slow 
multifocal 
segmental 
focal 30 
as part of 
another 
disease 
dystonia 
plus 
myoclonus sporadic and hereditary (DYT11, 15) forms 
7 
dystonia 
parkinson 
syndromes 
sporadic and hereditary (DYT3, 5, 12) forms 
secondary 
(sympto-
matic) 
e.g. caused by neurodegenerative disorders, drugs, ischemia, 
injury, psychogenic 
paroxys- 
mal sporadic and hereditary (DYT8, 9, 10) forms 
Table1. Different ways of classifying dystonia syndromes and how they frequently correlate, combined from 
Fahn et al. (1998), Bressman (2004), Tarsy and Simon (2006) and Schmidt et al. (2008). 
 
Cases are classified according to the topographic distribution of symptoms, age of onset and 
familial occurrence (de Carvalho Aguiar and Ozelius 2002). Late-onset dystonia typically 
develops after the age of 25, shows no family history and is most likely to remain localized as 
focal dystonia or as segmental dystonia. The most common types of focal dystonia are writ-
er’s cramp (Fig.1A), blepharospasm and torticollis (Fig.1B). Patients with an early-onset be-
fore the age of 25 often show a family history of dystonia and are most likely to develop gen-
eralized dystonia (primary torsion dystonia, PTD, Fig.1C). In most patients, movements be-
come worse during action or concentration and can be improved by relaxation or by a sensory 
 
Figure 1. Different types of dystonia, adapted from Breakefield et al. (2008): (A) Writer’s cramp 
is a form of task-specific adult-onset dystonia with disabling contractions of hand, finger and fore-
arm muscles during handwriting. (B) Torticollis is characterized by sustained or intermittent con-
tractions of the neck muscles forcing the head into an abnormal tilt. (C) Symptoms of child-
hood/adolescent-onset forms of dystonia like PTD start in one leg or arm and progress into other 
parts of the body leading to abnormal postures. 
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trick (geste antagoniste). 
Dystonia represents the third most common movement disorder. Primary focal dystonias oc-
cur in 30 of 100.000 people which makes them about ten times more common than primary 
generalized dystonias. However, a large number of cases remains un- or misdiagnosed 
(Greene et al. 1995; Defazio et al. 2004). 
Regarding medical treatment, some patients partially benefit from anticholinergic, GABAer-
gic or dopaminergic pharmacotherapy, but the treatment of choice for focal dystonias are re-
peated local injections of botulinum neurotoxin. For more severe or generalized cases, pallidal 
deep-brain stimulation is currently investigated with predominantly positive influences on the 
symptoms (Schrader et al. 2009). However, these approaches are symptomatic and no cure 
has been found so far because underlying disease mechanisms have not been fully understood. 
 
Monogenic types of dystonia: As seen in table 2, 16 gene loci have been described up to now 
as causes of monogenic forms of dystonia. Distinct clinical features have been described for 
each mutation (Klein 2008). Many of the monogenic dystonias are inherited in an autosomal-
dominant manner with limited penetrance suggesting that a ‘second hit’ (genetic or environ-
mental) is needed to trigger the disease. The reported gene loci have different prevalences 
with rare ones that have been found in some families only pointing to a founder mutation to 
others with a big spread in the population indicating a relatively high rate of de-novo muta-
tions (Klein and Ozelius 2002). The DYT1 mutation is present in about 70% of all hereditary 
PTD cases while the majority of primary adult-onset dystonias appears to be sporadic. 
 
Name Dystonia type OMIM Inheritance Locus Gene product 
DYT1 
 
Early-onset generalized torsion 
dystonia 
128100 AD 9q34 TorsinA 
DYT2 Autosomal recessive torsion 
dystonia 
224500 AR Unknown Unknown 
DYT3 Dystonia-parkinsonism (“lub-
ag”) 
314250 XR Xq13.1 Disease-specific changes in 
DYT3 region 
DYT4 ‘Non-DYT1’ dystonia (whis-
pering dystonia) 
128101 AD Unknown Unknown 
GCH1 
 
Dopa-responsive dystonia  128230 AD 14q22.1-2 GTP-cyclohydrolase1 
TH 
 
Segawa syndrome 191290 AR 11p15.5 Tyrosine hydroxylase 
DYT6 Adolescent-onset dystonia of 
mixed type 
602629 AD 8p21-22 Unknown 
DYT7 
 
Adult-onset focal dystonia 602624 AD 18p Unknown 
DYT8 Paroxysmal non-kinesigenic 
dyskinesia 
118800 AD 2q33-25 Myofibrillogenesis 
regulator 1 
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Name Dystonia type OMIM Inheritance Locus Gene product 
DYT9 Paroxysmal choreoathetosis 
with episodic ataxia and spas-
ticity 
601042 AD 1p21 Unknown 
DYT10 Paroxysmal kinesigenic chore-
oathetosis 
128200 AD 16p-q Unknown 
DYT11 
 
Myoclonus dystonia 604149 AD  7q11q25 ε-Sarcoglycan 
DYT12 Rapid-onset dystonia-
parkinsonism 
128235 AD 19q Na+/K+ATPaseα3subunit 
DYT13 
 
Multifocal/segmental dystonia 607671 AD 1p36 Unknown 
DYT15 
 
Myoclonus dystonia 607488 AD 18p11 Unknown 
DYT16 Young-onset dystonia-
parkinsonism 
612067 AR 2q31 PRKRA 
Table2. Genetically defined forms of dystonia and dystonia-plus adapted from Klein and Ozelius (2002) and 
Camargos (2008). AD autosomal dominant, AR autosomal recessive, XR X-linked recessive. 
 
Pathophysiology: Human brain specimen of dystonia patients revealed no signs of neuro-
degeneration in terms of overt atrophy, neuron loss or inflammation. Yet, post mortem studies 
in affected DYT1 PTD patients demonstrated slightly enlarged dopaminergic cell bodies in 
the substantia nigra (Rostasy et al. 2003) and perinuclear ubiquitin-positive inclusions in mid-
brain nuclei involved in motor activity (McNaught et al. 2004). These findings could not be 
confirmed in other forms of primary dystonia, suggesting that they might be an epiphenome-
non of the mutation rather than the general mechanism leading to a dystonic phenotype (Hol-
ton et al. 2008). In secondary dystonias, e.g. following cerebral ischemia or in spinocerebellar 
syndromes, regions affected by the disease can be identified neuropathologically. These indi-
cate that symptoms in primary dystonias may result from malfunctions in the basal ganglia, 
cerebellum, brainstem or parietal lobe (Geyer and Bressman 2006). 
MRI studies of dystonia showed enlarged basal ganglia, increased grey matter density of sen-
sorimotor areas, and altered activity patterns in motor areas during motor tasks (Draganski et 
al. 2003; Defazio et al. 2007). Transcranial magnetic stimulation (TMS) studies observed an 
increase in motor cortex excitability potentially resulting from impaired inhibitory signals 
(Ikoma et al. 1996). In PET studies, D2 dopamine-receptor binding was altered in the puta-
men pointing to dopaminergic abnormalities in dystonia (Perlmutter et al. 1997). 
Altered brain plasticity processes seem to be a major contributing factor in the pathophysiolo-
gy of dystonia. Most patients suffering from task-specific dystonia like writer’s cramp or mu-
sician’s dystonia report an overuse of the affected body region precedent to the onset of symp-
toms (Quartarone et al. 2006). In these patients, somatotopic organization of motor and senso-
ry areas is disorganized, sensorimotor inhibition is impaired and the formation of new synap-
tic connectivity is facilitated as revealed by transcranial brain stimulation. The fact that af-
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fected DYT1 PTD patients and non-affected mutation carriers show impairments in motor 
learning paradigms further indicates a central role of altered plasticity processes (Ghilardi et 
al. 2003). 
The efficacy of anticholinergic, GABAergic and dopaminergic agents is consistent with the 
alterations in these neurotransmitter systems. In addition, the effect of deep brain stimulation 
of the globus pallidus and, historically, of surgical pallidotomy also indicates the contribution 
of the basal ganglia in the pathophysiology. However, it cannot be concluded that these are 
the primary site of malfunction, since pallidal stimulation might simply override symptoms 
that are generated in upstream motor control systems (Breakefield et al. 2008). 
 
DYT1 mutation: It is not known whether different types of dystonia share a common patho-
physiology. Therefore, in this study we focused on DYT1 PTD which accounts for 70% of all 
cases of early-onset dystonia. Symptoms occur in 30-40% of all mutation carriers (reduced 
phenotypical penetrance) and start between 5 to 28 years of age. Triggers or risk factors for 
the onset are not known. Patients show no cognitive impairments and most retain the ability to 
walk with a more or less pronounced handicap (Kamm 2006). Mutation carriers older than 28 
are virtually free from the risk of developing symptoms (Bressman 2004). However, they 
show, like their affected relatives, an endophenotype of altered resting metabolic activity in 
the basal ganglia (Eidelberg et al. 1998) and slowed motor learning (Ghilardi et al. 2003). 
 
The DYT1 gene: The DYT1 mutation consists of an inframe deletion of a GAG triplet in the 
DYT1 gene (also called Tor1A) on chromosome 9q34 (Ozelius et al. 1997). DYT1 codes for 
the 332 amino acid protein torsinA (37.8kDa, fig. 2). The GAG deletion results in the loss of 
one of two adjacent C-terminal glutamic acid residues (number 302 and 303). TorsinA pos-
sesses a putative ATP-binding domain and an N-terminal signal sequence redirecting the pro-
tein to the endoplasmic reticulum (ER, Kustedjo et al. 2000). TorsinA has been attributed to 
the AAA+ (ATPase associated with a variety of cellular activities) protein superfamily (Oze-
lius et al. 1999). 
DYT1 shares more than 70% homology with the gene Tor1B coding for torsinB. Two addi-
tional members of the human Tor1A family are Tor2A on chromosome 9 and Tor3A on 
chromosome 1, encoding torp2A (~40kDa) and torp3A (~40 or 48kDa, alternative splicing), 
each with about 50% homology to torsinA and with as yet undetermined functions (Ozelius et 
al. 1999). 
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The DYT1 gene including its GAG deletion site is highly conserved in species including 
C.elegans, drosophila and rodents which probably implies a functional significance. All 
members of the torsinA family show a distant relation to the eukaryotic heat shock protein 
100 family. Its members act as molecular chaperones: They are upregulated during oxidative 
stress in the cell and are able to undo protein aggregation (Maurizi and Xia 2004).  
 
Wildtype torsinA functions: In humans, torsinA is expressed ubiquitously in all tissues; in the 
CNS, expression can be detected in all neurons, but not in glial cells (Ozelius et al. 1997). 
TorsinA mRNA and protein levels are highest in dopaminergic neurons of the pars compacta 
of the substantia nigra (SNc), in the striatum, in Purkinje cells of the cerebellum and in nora-
drenergic cells of the locus coeruleus – similarly in humans, rats and mice (Augood et al. 
1998; Augood et al. 1999; Shashidharan et al. 2000; Konakova et al. 2001; Konakova and 
Pulst 2001; Andersen 2003; Augood et al. 2003). On the subcellular level, torsinA is found in 
the lumen of the ER and enriched in presynaptic terminals (Hewett et al. 2000; Augood et al. 
2003; Hewett et al. 2003). TorsinA is upregulated in response to oxidative stress, but – unlike 
heat shock proteins – not in response to other types of stressors (Hewett et al. 2003).  
 
Effects of mutant torsinA: When overexpressed in a neuronal mouse cell line, mutant, but not 
wildtype torsinA led to perinuclear inclusions and flattened cell shapes (Hewett et al. 2000; 
Kustedjo et al. 2000). Perinuclear inclusions have also been found in brain tissue of DYT1 
patients in the SNc and the locus coeruleus. Aggregates were positive for torsinA, ubiquitin (a 
 
 
Figure 2. The torsinA protein. (A) Schematic representation of the torsinA protein domains with 
about 40 hydrophobic amino acids in the N-terminal region, the ATP-binding domain flanked by 
its two conserved motifs and two additional motivs conserved with the HSP 100 family. (B) Tors-
inA monomers predicted to form six-membered ring structures within the ER. Loss of the C-
terminal glutamic acid residue (red) might interrupt protein structure or interaction with partners. 
Adapted from Leung et al. (2001) and Breakefield et al. (2001). 
A 
B 
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mediator of post-translational protein modification and degradation) and for the nuclear enve-
lope marker lamin A/C consistent with the findings in cell culture. Despite of these inclusions, 
no signs of neurodegeneration and no signs of inflammation were present in these patients 
(McNaught et al. 2004). 
In primary fibroblasts of DYT1 patients, torsinA was abnormally localized around the nucleus 
and impaired secretory processes (Hewett et al. 2006). Specific knock-down of mutant tor-
sinA by siRNA as well as additional overexpression of wildtype torsinA restored this function 
to normal (Hewett et al. 2008). This indicates a dominant-negative role of the mutant protein, 
but up to now, implicated mechanisms and pathways are not known. 
 
Animal models of dystonia: Surprisingly, all existing animal models that show a dystonic 
phenotype carry spontaneous mutations in genes that are not known from human dystonia. 
Nevertheless, some parallels to the human disease have been found in their analyses. The dt/dt 
mouse, for example, is characterized by loss of the hemidesmosomal protein dystonin result-
ing in an autosomal recessive phenotype with dystonic postures and neuronal degradation. 
Dystonin has been found to interact with the cytoskeleton and with the nuclear envelope 
which reminds of the functions proposed for torsinA (Raike et al. 2005; Breakefield et al. 
2008). 
Further insight into the pathophysiology of human hereditary dystonias has been provided by 
animal models of DYT1 (for which most of the work has been done), DYT5, DYT11 and 
DYT12. An advantage of modeling DYT1-associated dystonia is the high conservation of this 
protein (Raike et al. 2005). Main strategies have been knock-in, knock-out and transgenic 
approaches; a comprehensive summary is shown in table 3 (Zhao et al. 2008b). 
Animals totally lacking the wildtype allele (i.e., Tor1A-/-, Tor1AΔGAG/ΔGAG and Tor1AΔGAG/-) 
were postnatal lethal due to feeding unability. This suggested a specific failure in executing 
motor actions since all structures of the CNS in these mice were normally developed (Good-
child et al. 2005). 
Heterozygous knock-in mice showed hyperactivity and performed worse in fine motor coor-
dination tests. Immunohistologically, ubiquitin- and torsinA-positive aggregates were found 
in the pontine nuclei of males only and neurochemically, the dopamine metabolite homovanil-
lic acid (HVA) was slightly reduced in the striatum (Dang et al. 2005). Consistently, DYT1 
knock-down mice with reduced expression of the DYT1 gene showed similar behavior and 
neurochemistry results as heterozygous knock-in mice (Dang et al. 2006). 
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Partly different morphological, behavioral and neurochemical results were obtained in three 
transgenic murine DYT1 models that have been published so far. Human mutant (ΔGAG) 
torsinA driven by the neuron-specific enolase (NSE) promoter led to pathological and behav-
ioral abnormalities in a subset of animals (Shashidharan et al. 2005). Human cytomegalovirus 
(CMV) promoter-driven torsinA transgenic mice showed no histological abnormalities, but 
minor changes of striatal dopamine and acetylcholine neurotransmission (Sharma et al. 2005; 
Pisani et al. 2006; Balcioglu et al. 2007; Zhao et al. 2008b). 
Finally, in a third model which was used for this study, transgenic human mutant (hΔGAG, 
hMT) or transgenic human wildtype torsinA (hWT) was overexpressed under control of the 
murine prion protein promoter (Grundmann et al. 2007). The hWT group is considered as a 
more suitable control compared to wildtype animals. Both lines showed neuropathological, 
and neurochemical abnormalities as well as minor changes of spontaneous behavior (compare 
table 3). In both lines, motor circuit integrity as measured by diffusion tensor imaging was 
found to be impaired in striatum, cerebellum and motor cortex. 
In summary, results from transgenic torsinA models show that mutant human torsinA causes 
altered levels of striatal dopamine and its metabolites and possibly also hyperactivity. 
 
 
Model Construct Morphology Behavior Neurochemistry 
DYT1 
transgenic 
(Shashidharan et 
al. 2005) 
7.1 kb fragment from the 
pNSE-Ex4 vector con-
taining the neuron-
specific enolase promoter, 
human mutant (ΔGAG) 
torsinA-cDNA and SV40 
polyA signal 
Ubiquitin- and torsinA-
IR perinuclear aggre-
gates and inclusion 
bodies in the peduncu-
lopontine nucleus, pons 
and periaqueductal gray 
40% of transgenic 
mice from each line 
displaying dystonic 
movements of 
limbs with self-
clasping, circling 
behavior, and hy-
peractivity 
↓ striatal DA in 
transgenic animals 
that exhibited an 
abnormal behavioral 
phenotype 
↓ striatal 
DOPAC/DA ratio in 
all transgenic mice 
DYT1 
transgenic 
(Sharma et al. 
2005; Pisani et 
al. 2006; 
Balcioglu et al. 
2007; Zhao et al. 
2008b) 
Human wild-type (hWT) 
or mutant (ΔGAG) torsi-
nA-cDNAs inserted into 
pcDNA3.1 under the 
human cytomegalovirus 
immediate early promoter 
No torsinA-positive 
inclusions or increased 
staining around the 
nuclear envelope (NE) 
Reduced ability to 
learn motor skills in 
an accelerating 
rotarod paradigm 
and beam-walking 
test 
↑ striatal 
DOPAC/DA ratio 
↓ amphetamine-
induced striatal 
extracellular DA 
levels 
altered responses to 
DA2-receptor acti-
vation 
DYT1 
knock-in 
(Dang et al. 
2005) 
Exon 5 in the targeting 
vector construct carrying 
a GAA deletion at codon 
302; PGKNeoSTOP cas-
sette with a false transla-
tion signal, splice donor 
site and poly(A) tail in-
serted into intron 4 
Ubiquitin- and torsinA-
containing aggregates 
in pontine nuclei of 
male DTY1 knock-in 
mice 
Deficient perfor-
mance on the beam-
walking test, open-
field hyperactivity 
↓ striatal HVA 
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Model Construct Morphology Behavior Neurochemistry 
DYT1 
knock-out 
(Goodchild et al. 
2005) 
Exons 2–4 of DYT1 re-
placed by a cassette con-
taining Neo and IRES-tau 
LacZ sequences 
Vesicles within the 
neuronal NE that ap-
pear to derive from the 
inner nuclear mem-
brane 
Homozygotes lethal 
postnatally 
n/a 
DYT1 
knock-in (Good-
child et al. 2005) 
Exon 5 in the targeting 
construct carries a GAG 
deletion. Neo cassette 
was inserted into intron 4 
of DYT1 
Homozygotes exhibit-
ing vesicles within the 
neuronal NE that ap-
pear to derive from the 
inner nuclear mem-
brane 
Homozygotes lethal 
postnatally 
n/a 
DYT1 
knock-down 
(Dang et al. 
2006) 
PGKNeoSTOP cassette 
with false translation 
signal, splice donor site 
and poly(A) tail inserted 
into intron 4 of DYT1, 
recombination 5′ to an 
Exon 5 GAA deletion 
n/a Horizontal hyperac-
tivity, 
↑ slips on a beam-
walking test 
↓ striatal DOPAC 
DYT1 
transgenic 
(Grundmann et 
al. 2007) 
Human wild-type (hWT) 
and mutant (hΔGAG) 
torsinA-cDNAs inserted 
into pBluescript II SK-
vector under 3.4 kb frag-
ment of murine prion 
protein promoter and 
tagged C-terminally with 
V5-His 
hWT and hΔGAG: 
Inclusion-like for-
mations in brainstem 
nuclei, torsinA-IR lo-
calized to the NE, NE 
abnormalities, disrupted 
white matter connectiv-
ity 
hWT mice: hypoac-
tivity, short stride 
length, prolonged 
traversal times on 
beam-walking 
 
hΔGAG mice: hy-
peractive, defects 
on rotarod testing 
hWT mice: 
↓ striatal DA, sero-
tonine and 5-HIAA; 
↓ brainstem HVA.  
 
hΔGAG mice: 
↑ brainstem 
DOPAC, serotonine 
and 5-HIAA 
Table3. Summary of murine DYT1 models that have been described to date, adapted from Zhao et al. (2008b) 
and Breakefield et al. (2008). DA dopamine, DOPAC Dihydroxyphenylacetic acid, 5-HIAA 5-
Hydroxyindoleacetic acid, HVA Homovanillic acid, IR immunoreactive, NE Nuclear envelope. 
 
 
2. Adult neurogenesis 
Background: Adult neurogenesis is the generation of new neurons in the adult brain. Until the 
1990s, most neuroscientists’ view was that all neurons were produced during embryonic and 
postnatal development and that no new neurons could be generated afterwards: “In the adult 
nerve centers, the nerve paths are something fixed and immutable: everything may die, noth-
ing may regenerate” (Ramón y Cajal 1928). However, today it is accepted that ongoing neu-
ronal production is found in the adult mammalian brain throughout life within two neurogenic 
areas. As mature neurons have not been shown to undergo cell division, the ongoing genera-
tion of mature neurons requires the presence of neural stem cells. These are defined by their 
ability of unlimited self-renewal by symmetric or asymmetric division. Self-renewal of neural 
progenitor cells is limited; they are able to rapidly proliferate, but will finally all differentiate 
into neurons and glial cells. Neural stem and progenitor cells are summarized by the term pre-
cursor cells since they often cannot be distinguished [reviewed by Ming and Song (2005) and 
Zhao et al. (2008a)]. 
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Methods to detect newly generated neurons: In the 1960s, the first indications for the adult 
production of new neurons were found by [H³]-thymidine incorporation into replicating cells 
(Friedkin et al. 1956; Messier et al. 1958; Altman and Das 1965a). The thymidine-analog 
bromodeoxyuridine (BrdU) can be detected by immunohistochemistry and thus allows abso-
lute quantification and proof of colocalization by multiple stainings (Kaplan and Hinds 1977; 
Gratzner 1982; Cameron et al. 1993; Kuhn et al. 1996). Before its use in neurogenesis re-
search, it had already been established as a marker for cell proliferation in vivo and in vitro 
(Dolbeare 1995) since it does not influence transcription and viability of proliferating cells 
(Dunn et al. 1954; Zamenhof and Gribiff 1954). The sensitivity of the method depends on the 
applied dose of BrdU: too low doses miss dividing cells or will be diluted in subsequently 
dividing cells whereas too high doses overload cells and induce apoptosis. Therefore, injec-
tion paradigms usually require daily applications for 1-7 days depending on the gap between 
injections and tissue fixation (Cameron and McKay 2001). As drawbacks, analyses cannot be 
conducted in alive animals since BrdU detection needs tissue fixation and confocal microsco-
py is required for a proper attribution of a BrdU-positive nucleus to the neuronal-maker-
positive cytoplasm (Rakic 2002). Other approaches for the detection of newborn cells include 
labeling by retroviruses and labeling of cells by genetic manipulations (Lewis and Emerman 
1994; Tashiro et al. 2006). Neuroblasts can also be identified due to the expression of specific 
markers, e.g. doublecortin [DCX, (Couillard-Despres et al. 2005)]. 
 
Sites of ongoing neurogenesis in the adult mammalian brain: Neurogenesis in the intact 
adult mammalian brain is restricted to two neurogenic regions. Adult olfactory neurogenesis 
occurs in the subventricular zone (SVZ) below the ependyma of the lateral wall of the lateral 
ventricles where neural stem and progenitor cells reside (Fig. 2 A, B). From there, newly gen-
erated cells migrate within the rostral migratory stream (RMS) into the olfactory bulb where 
they terminally differentiate and integrate into the local network (Altman and Das 1965b; 
Corotto et al. 1993; Curtis et al. 2007). Stem and progenitor cells of adult hippocampal neuro-
genesis reside in the subgranular zone (SGZ) medial of the granule cell layer of the dentate 
gyrus (GCL; Fig. 2 A, C). Following short-distance tangential migration within the SGZ, new 
cells move radially into the GCL where they become new granule cells. They receive inputs 
on their dendrites from association cortex and entorhinal cortex areas via the perforant path-
way and relay axonal output into CA3 pyramidal cell layer via the mossy fiber pathway (Alt-
man and Das 1965a; Eriksson et al. 1998; van Praag et al. 2002).  
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Similar differentiation stages are present in the two neurogenic regions. In both systems, the 
slowly cycling putative stem cells (“B-cells” in SVZ, “type1 cells” in DG) are GFAP-, Hes5- 
and nestin-positive (Lendahl et al. 1990; Doetsch et al. 1999a; Doetsch et al. 1999b; Lugert et 
al. 2010). The derived transiently amplifying progenitor cells (“C-cells” in SVZ/RMS, “type2 
cells” in DG) are GFAP-negative and downregulate nestin. Proliferating cell nuclear antigen 
(PCNA) is a marker for neural progenitor proliferation (Hall et al. 1990). With their specifica-
tion to the neuronal lineage and onset of migration, precursor cells upregulate DCX and the 
polysialylated form of the neural cell adhesion molecule [PSA-NCAM; “A-cells in 
SVZ/RMS, “type3 cells” in DG (Tomasiewicz et al. 1993; Meyer et al. 2002)]. Doublecortin 
is a microtubule-associated protein found primarily in the leading processes and growth cones 
of neurons (Bai et al. 2003; LoTurco 2004; Schaar et al. 2004). As soon as the cells have 
reached their target, have become postmitotic and start extending axons and dendrites, DCX 
and PSA-NCAM are downregulated and mature neuronal markers like neuron-specific eno-
lase (NSE) and neuronal nuclei (NeuN) are upregulated (Mullen et al. 1992). 
Modulation: A variety of endogenous and exogenous factors are regulators of adult neuro-
genesis. The baseline rate of new hippocampal neurons during adulthood is significantly af-
fected by genetic background of the animal with huge differences between wild-type and in-
bred laboratory strains (Kempermann and Gage 2002). Besides, aging is the strongest nega-
tive regulator of adult neurogenesis in both SVZ and SGZ causing an rapid decline of the 
number of new surviving neurons with age (Kuhn et al. 1996; Enwere et al. 2004; Kemper-
mann 2011). Finally, environmental stimuli also modulate adult neurogenesis, e.g. stress 
(Mirescu and Gould 2006), environmental enrichment and physical activity (Kempermann et 
al. 1997; van Praag et al. 1999). As seen in table 4, a variety of neuroactive compounds has 
also been shown to modulate proliferation, differentiation and survival of new neurons, with 
yet unclear physiological relevances (Ming and Song 2005). 
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Figure 3. Schematic drawing of the two neurogenic zones of the adult mammalian CNS. (A) 
Neural stem and progenitor cells reside within the SGZ of the DG and within the SVZ of the lateral 
ventricles. (B) In the SVZ, the neural stem and progenitor cells proliferate (1) and differentiate (2) 
towards a glial or neuronal (neuroblast) fate. From there, the immature neurons migrate along the 
astrocyte-ensheated RMS into the OB (3) where they radially move into the GCL or the GLOM 
and integrate into synaptic circuits as new granule or periglomerular neurons, respectively (4). (C) 
In the hippocampus, stem cells proliferate within the SGZ (1). Deriving neuroblasts (2) migrate 
radially into the DG (3). There, the immature neurons extend their axon along the mossy fiber 
pathway toward the CA3 pyramidal layer and their dendrites into the molecular layer of the DG 
(4). After complete synaptic integration, the new neurons become mature granule cells (5). Figures 
adapted from Ming and Song (Ming and Song 2005). 
A 
B 
C 
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Regulatory factors Impact Reference 
Hormones   
   Corticosterone SGZ proliferation ↓ (Cameron and Gould 1994) 
   Estrogen SGZ proliferation ↑ (Tanapat et al. 1999) 
Neurotransmitters   
   Dopamine SVZ + SGZ proliferation ↑ 
(Baker et al. 2004; Hoglinger et al. 
2004; Van Kampen et al. 2004; 
Winner et al. 2006) 
   Serotonin SVZ + SGZ proliferation ↑ (Banasr et al. 2004) 
   Acetylcholine SVZ + SGZ survival ↑ (Cooper-Kuhn et al. 2004) 
   Glutamate SGZ proliferation ↓ (Nacher and McEwen 2006) 
Growth factors   
   FGF-2 and EGF SVZ proliferation ↑ (Kuhn et al. 1997) 
   VEGF SVZ + SGZ survival ↑ (Schanzer et al. 2004) 
   IGF-1 SGZ survival ↑ (Aberg et al. 2000) 
Table4. General influence of different neuroactive compounds on adult neurogenesis: ↓ = decrease, ↑ = increase. 
 
Putative functions of adult neurogenesis: Hypothetically, the integration of new neurons 
offers a profound form of structural plasticity, making adult neurogenesis a possible contribu-
tor to the formation of memories. In the hippocampus and the SVZ/OB, behavioral or phar-
macological modulation of neurogenesis is accompagnied by changes in the performance in 
memory tasks and by changes in long-term potentiation (van Praag et al. 1999). Accordingly, 
newly generated mature neurons exhibit facilitated induction and larger amplitudes of long-
term potentiation (Schmidt-Hieber et al. 2004). Computational and behavioral analyses of 
adult hipppocampal neurogenesis suggest a role in preventing different memories from inter-
fering with each other (Wiskott et al. 2006) and in the separation of memories that are related 
in time or space (Aimone et al. 2009; Clelland et al. 2009; Deng et al. 2010; Aimone and 
Gage 2011; Sahay et al. 2011). Adult olfactory neurogenesis seems to be independent from its 
hippocampal counterpart, but has also been linked to the formation of new – olfactory – 
memories (Rochefort et al. 2002; Enwere et al. 2004). 
 
Neurodegenerative diseases affecting adult neurogenesis: As indicated by the mass of regu-
latory influences on adult neurogenesis, profound changes have been detected in some disor-
ders of the CNS including neurodegenerative diseases (table 5, Winner et al. (2011)). 
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Model Impact Reference 
Acute neurological diseases   
   Cerebral ischemia SVZ + SGZ proliferation ↑ 
migration toward the lesion 
(Arvidsson et al. 2002) 
   Temporal lobe epilepsy SGZ proliferation + survival ↑ 
neuroblast dispersion in hippocam-
pus 
(Parent et al. 1997) 
   Inflammation SGZ proliferation + survival ↓ (Monje et al. 2003) 
 
Huntington’s disease 
  
   Human patients SVZ proliferation ↑ (Curtis et al. 2003) 
   Lesion animal model SVZ proliferation ↑ (Tattersfield et al. 2004) 
   Genetic animal models SVZ + SGZ survival ↓ (Gil et al. 2004; Lazic et al. 2004; 
Gil et al. 2005; Kohl et al. 2010) 
Alzheimer’s disease   
   Human patients SGZ proliferation ↑ (Jin et al. 2004b) 
   Genetic animal models SGZ/SVZ proliferation/survival ↓↑ (Haughey et al. 2002a; Haughey et 
al. 2002b; Jin et al. 2004a; 
Boekhoorn et al. 2006) 
Parkinson’s disease   
   Human patients SVZ + SGZ proliferation ↓ (Hoglinger et al. 2004) 
   Lesion animal models SVZ proliferation ↓ (Baker et al. 2004; Winner et al. 
2006) 
   Genetic animal models SGZ/SVZ 
proliferation/survival ↓/↔ 
(Winner et al. 2004; Nuber et al. 
2008; Winner et al. 2008b; Marx-
reiter et al. 2009) 
Table 5. Influence of different brain pathologies and neurodegenerative diseases on adult neurogenesis in animal 
models and humans: ↓ = decrease, ↑ = increase. 
 
3. Potential effects of transgenic torsinA on adult neurogenesis 
The aim of this work was to investigate potential changes in the population of adult neural 
precursors concerning their proliferation and survival in the transgenic hWT and hMT mouse 
models (Grundmann et al. 2007). 
 
Hypotheses: For further insight into the role of adult neurogenesis in DYT1, we addressed the 
following hypotheses and respective aims: 
I. In hMT and hWT mice, transgenic torsinA is overexpressed in the neurogenic regions. 
Aim: Immunohistochemical detection of transgenic and endogenous torsinA in the 
SVZ, OB and DG. 
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II. Transgenic wildtype or mutant torsinA is expressed within neural progenitor cells dur-
ing migration and differentiation. 
Aim: Colocalization analysis of transgenic torsinA and markers of different stages of 
neuroblast differentiation. 
III. DYT1-related striatal pathology leads to ectopic neuroblast migration. 
Aim: Qualitative analysis of the distribution of newly generated neurons and quantifi-
cation of striatal neuroblasts.  
IV. Transgenic wildtype or mutant torsinA impairs adult neurogenesis. 
Aim: Quantification of proliferation, survival and differentiation of newly generated 
neurons in the hippocampus and the SVZ/OB. 
 
Transgenic expression of torsinA: In the initial characterization of these mouse models, tor-
sinA expression was highest in pons, brainstem, cerebellum and the OB (Grundmann et al. 
2007). Weaker immunostaining was observed in the striatum and the hippocampus. There-
fore, it is important to first confirm the expression of torsinA in the neurogenic areas of these 
mouse models (aim I). 
 
DYT1 has cell-autonomous effects on adult neurogenesis: TorsinA expression in mice and 
rats is highest from embryonic day 15 to postnatal day 14 and shows a site-specific correlation 
with the peaks in neurogenesis, neuronal migration and initial synaptic formation in striatum 
and hippocampus (Xiao et al. 2004; Vasudevan et al. 2006). As expression levels of torsinA 
rapidly decrease thereafter until postnatal day 30, it is thought to exert functions in neural 
development. Accordingly, torsinA was shown to regulate neuronal migration during embry-
onic development (Bhide et al. 2008). Therefore, it is important to examine if in the mouse 
models, transgenic torsinA is overexpressed also within adult neural progenitor cells (aim II)  
 
Striatal neuroblast migration: Under different pathological conditions, e.g. models of Hun-
tington’s disease and ischemia and following the application of growth factors, high DCX-
expression has been shown in the striatum in association with newly generated cells. These 
cells were migrating from the SVZ into the diseased striatum with or without ending in neu-
ronal maturity (Arvidsson et al. 2002; Winner et al. 2008a; Kohl et al. 2010). Striatal dysfunc-
tion is a hallmark of DYT1-dystonia patients and has been demonstrated by MRI and TMS 
(Perlmutter et al. 1997; Draganski et al. 2003; Perlmutter and Mink 2004; Defazio et al. 
2007). In hWT and hMT mice, striatal pathology includes altered neurotransmitter levels and 
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disrupted white matter connectivity (Grundmann et al. 2007). Consequently, in hWT/hMT 
mice, neuroblasts might also be redirected into the diseased striatum (aim III). 
 
Intraneuronal torsinA inclusions affecting neural progenitors: Intraneuronal aggregates 
were observed in previously characterized transgenic animal models overexpressing human α-
synuclein. In these models, survival of newly generated neurons is decreased in the OB and in 
the SGZ, correlating with increased cell death in these regions (Winner et al. 2004; Nuber et 
al. 2008; Marxreiter et al. 2009). TorsinA-positive inclusions are a histopathological feature in 
DYT1 patients and in the hWT/hMT mouse models (McNaught et al. 2004; Grundmann et al. 
2007). Therefore, torsinA might lead to reduced survival of newborn neurons due to the for-
mation of intraneuronal inclusions (aim IV). 
 
Cell non-autonomous torsinA leads to reduced neurogenesis: Aside from an endogenous 
influence on adult neural precursor cells, the DYT1 mutation might also influence adult neu-
rogenesis by a cell non-autonomous mechanism. TorsinA is highly expressed in the OB of 
hWT and hMT mice; thus, the “diseased” environment could lead to impaired integration and 
survival of newborn neurons (aim IV). 
 
DYT1 alters neurogenesis due to altered dopamine or hyperactivity: Imbalances of the stria-
tal dopaminergic system have been found both in PTD patients and in DYT1 animal models. 
Lack of striatal dopamine is an established downregulator of adult SVZ neurogenesis both in 
animal models and PD patients whereas excess striatal dopamine seems to have almost no 
upregulatory effect (Borta and Hoglinger 2007). Therefore, DYT1-induced changes in striatal 
dopamine might affect the rate of SVZ neurogenesis as a cell-non-autonomous effect. In the 
hWT mouse model, striatal dopamine levels are decreased which is therefore expected to ex-
ert a negative impact on SVZ neurogenesis (aim IV). 
In addition to neurochemical changes within the brain, the hyperactive phenotype of DYT1 
transgenic mice as a form of physical activity could cause a secondary increase of adult hip-
pocampal neurogenesis. As the survival-promoting effect of physical activity is specific for 
the hippocampus, it would have no influence on SVZ/OB neurogenesis (aim IV). 
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 1 4 29 experiment (days) 
 
 4  5 age (months) 
BrdU i.p. Perfusion 
Immunohistochemistry: 
V5:   cell expressing the transgene 
TorsinA: cell expressing endogenous or 
transgenic TorsinA  
BrdU:  surviving newborn cell 
PCNA:  proliferating cell 
DCX:  neuronally determined precur-
sor cell 
Immunofluorescence: 
V5/DCX:  neuroblast expressing the 
transgene 
BrdU/NeuN: newly generated neuron 
 
Analysis 
 
C. Materials and Methods 
 
The experimental part of this work was conducted in the laboratories of the department of 
neurology of the university of Regensburg according to the following paradigm: 
1. Animals 
A total of 21 C57BL/6N mice were provided by the Department of Medical Genetics at the 
University of Tübingen, Germany which has previously characterized them (Grundmann et al. 
2007). Six of them were control animals, eight were transgenic for human mutant torsinA 
(hMT group) and seven were heterozygously transgenic for human wildtype torsinA (hWT 
group). 
In brief, transgenic animals had been generated by means of a vector consisting of the murine 
prp promoter, the human DYT1 sequence (wildtype or mutant) to be expressed under the con-
trol of this promoter and the V5-His tag as a marker. The construct had been injected into the 
pronucleus of a fertilized egg produced by a superovulated female mouse. It randomly inte-
grates into the DNA by non-homologous recombination. Microinjected oocytes are trans-
ferred into pseudo-pregnant females mated with vasectomised males. Less than 20% of the 
offspring are founder mice containing the foreign DNA in all their tissues and germ lines 
(founder mice). Breeding had been continued for a few generations to ensure that the 
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transgene is repetitively propagated within the germ line and to achieve genetic uniformity 
(Lodish 2008). 
Genotypes were determined by ear biopsy PCR. Genomic DNA was isolated from the tissue. 
Human wildtype and human mutant torsinA-cDNA were positive controls and biopsy material 
of nontransgenic animals were negative controls. DNA was isolated using High Pure PCR 
Template Preparation Kit (Roche Diagnostics GmbH, Hamburg, Germany). With the primer 
3696_PrP_F (TTTGGAATATGTTTGCGCTG) combined with 2026_torA_seq1_R 
(TGTTCAGACCACCCTCGTAA) or 2028_torA_seq2_R (GCTTGATGTCTTCCCTCTGC), 
a 600bp segment or a 830 bp within the human torsinA coding sequence was amplified ac-
cording to the following conditions: 94°C for 1 min, 55°C for 1 min and 72°C for 1 min, 35 
cycles (Grundmann et al. 2007). 
In each group, genders were distributed equally (hMT: 4 ♂, 4 ♀; hWT: 4 ♂, 3 ♀; control: 3 
♂, 3 ♀). One male animal of the control group died during the experimental phase for un-
known reasons, resulting in a control group size of 5. 
The inserted constructs consisted of the murine prion protein gene promoter including exon 1, 
intron 1 and part of exon 2 which are necessary to promote a high rate of transcription (Bay-
butt and Manson 1997). Constructs contained the genes encoding either human wildtype tor-
sinA (hWT group) or human mutant torsinA (hMT group) followed by a V5-His tag (Fig. 4). 
The V5-His tag is a marker protein for visualization of the transgene. The V5-epitope is a 14 
amino acid peptide and the attached His tag is a 6 amino acid polyhistidine sequence. 
All experiments were carried out in accordance with the European Communities Council Di-
rective of 24 November 1986 (86/609/EEC) and were approved by the local governmental 
commission for animal health. Animals were kept in normal light dark cycles of 12h in stand-
ard laboratory cages and had free access to food and water. 
 
Figure 4. The two constructs used for overexpressing human wildtype torsinA (hWT) or hu-
man mutant torsinA (hMT) under control of the murine prion protein promoter (prp-promoter). 
Both constructs are identical except for the deletion of the GAG-triplet in hMT. Reprinted from 
Grundmann et al. (2007). 
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2. BrdU labeling and tissue processing 
BrdU labeling: Powdery 5-bromo-2-deoxyuridine (BrdU, Sigma-Aldrich, Steinheim, Germa-
ny) was completely dissolved at 10mg/mL in sterile saline (0,9% w/v NaCl) under stirring and 
heating. From days 1 to 4, all animals received daily intraperitoneal injections of BrdU (50mg 
BrdU per kg body weight) to label dividing cells. 
Brain processing: 28 days after the first BrdU injection, all animals were sacrificed. 0.4mL of 
a mixture of anaesthetics consisting of ketamine [Ketanest®] (20.38mg/mL), xylazine 
[Rompun®] (5.38mg/mL) and acepromacin [Vetranquil®] (0.29mg/mL) dissolved in sterile 
saline (0.9% w/v NaCl) was applied intraperitoneally. When animals were completely anes-
thetized and showed no more pain reflexes, median sternotomy was performed and the heart 
was uncovered. The left ventricle was incised at the apex and an atraumatic perfusion needle 
was inserted into the aorta. NaCl (0.9% w/v) was applied via the perfusion needle for 10 
minutes followed by 15 minutes of 4% paraformaldehyde to fix tissue. Then, skull and supe-
rior vertebral canal were opened and brains including hindbrain and medulla were carefully 
dissected. After separating brains and spinal cords, they were stored overnight in 4% para-
formaldehyde for complete penetration of the tissue. Finally, tissue was stored in a solution of 
30% sucrose in 0.1M PO4-buffer at 4°C. 
Microtomy: For the creation of tissue sections with a thickness of 25µm, brains were cut into 
two hemispheres – left hemispheres of 2 animals per group were used for coronal sections 
ranging from forebrain (excluding the OB) to midbrain while the remaining left hemispheres 
and all of the right hemispheres were utilized for sagittal sections ranging from the olfactory 
bulb to cerebellum and hindbrain. Tissue sections were obtained on a sliding microtome 
(SM2000R, Leica, Wetzlar, Germany) set to a thickness of 25µm and cooled by dry ice. Sec-
tions were stored in cryoprotectant solution (25% ethylene glycol, 25% glycerol in 0.1M 
phosphate buffer, pH 7.4) at 4°C. 
 
3. Immunohistochemistry 
Principles of immunohistology: For immunohistological detections, a primary antibody is 
used first to specifically bind to the desired antigen followed by the application of a secondary 
antibody that is chemically coupled with an enzyme or a flourochrome and that is raised in a 
different species. In enzymatic immunohistochemistry, an enzyme transforms the added 
chromogen into an insoluble, stable product and thus provides a color signal at the location of 
the antigen. The most widely used enzymes are horseradish peroxidase (HRP) with the chro-
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mogen 3,3′-diaminobenzidine (DAB) generating a brown precipitate and alkaline phosphatase 
(AP). For immunoflourescence stainings, secondary antibodies are directly coupled to a 
flourochrome that emits light at a certain wavelength after excitation. The most common 
flourochromes are fluorescein isothiocyanate (FITC) which is excited at 490nm and emits at 
550nm (green) and tetramethyl-rhodamineisothiocyanate (TRITC) which is excited at 520-
554nm and emits at 582nm (red). Diamino-phenylindole (DAPI) or propidiumiodide (PI) are 
used as fluorescent nuclear counterstains (Lang 2006). Signals can be increased, for example 
by a biotin-streptavidin kit. A biotin-coupled secondary antibody has to be used and in an 
intermediate step, a mixture of enzyme- or fluorochrome-coupled biotin and excess streptavi-
din binds to biotin on the secondary antibody. As avidin has four binding sites for biotin, a 
“lattice” of biotin and streptavidin is formed and a multitude of enzymes or fluorochromes 
will be bound to the secondary antibody resulting in a higher signal (Hsu et al. 1981). 
Immunoperoxidase stainings: In this work, the following primary IgG-antibodies and final 
dilutions were used for enzymatic immunostainings: monoclonal antibody against BrdU de-
rived from rat in a dilution of 1:500 (rat α-BrdU monoclonal, Oxford Biotechnology, Oxford, 
UK), mouse α-NeuN (1:500), goat α-DCX polyclonal (1:250), mouse α-PCNA monoclonal 
(1:500, both Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse α-V5 (1:1000, Invi-
trogen, Carlsbad, CA, USA), mouse α-torsinA (1:50, D-M2A8, Cell Signaling Technology 
Inc., Danvers, MA, USA). Goat α-DCX polyclonal was directed against the C-terminal part of 
the human doublecortin protein, but also detects mouse and rat doublecortin because of the 
high homology between the species. Mouse α-torsinA antibody had been generated by im-
munization with an N-terminal fusion construct of amino acids 51-324 of torsinA with the 
maltose binding protein (Hewett et al. 2000; Hewett et al. 2003; Hewett et al. 2004). The fol-
lowing secondary antibodies were applied: donkey α-rt-IgG biotinylated, donkey α-goat-IgG 
biotinylated and donkey α-mouse-IgG biotinylated (all diluted 1:500, Jackson Immuno Re-
search, West Grove, PA, USA). 
Free-floating sections were transferred from the cryoprotectant solution into tris-buffered sa-
line (TBS: 0.15M NaCl, 0.1M Tris–HCl, pH 7.4 in dH2O) and repeatedly washed in TBS. 
Next, they were treated with 0.6% H2O2 (Merck KGaA, Darmstadt, Germany) in TBS for 
30min at room temperature to abolish any endogenous peroxidase activity within the tissue 
that could transform the chromogen resulting in a false-positive signal. In a blocking step after 
another washing step in TBS, sections were incubated in 3% normal donkey serum (PAN Bio-
tech GmbH, Aidenbach, Germany) and 0.1% Triton-X-100 (Sigma, Steinheim, Germany) in 
TBS for 30min at room temperature. By this means, binding sites of mouse tissue that react 
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unspecifically with donkey-derived immunoglobulins are occupied by unlabeled antibodies. 
Tissue was transferred into a solution of the primary antibody (rat α-BrdU, goat α-DCX, 
mouse α-PCNA, mouse α-V5 or mouse α-TorsinA) diluted in blocking buffer. After an incu-
bation time of 12h at 4°C and a washing step in TBS, the secondary antibody diluted in block-
ing buffer was applied for 1h at room temperature. Following another washing step in TBS, 
avidin-biotin-peroxidase complex (1:100 in TBS, Vectastain Elite PK-6100, Vector Laborato-
ries, Burlingame, CA, USA) was applied for 1h at room temperature. Finally, peroxidase de-
tection was performed for 7min with 25mg/mL 3,3′-diaminobenzidine in 0.01% (v/v) H2O2 
and 0.04% (w/v) NiCl2 (DAB peroxidase substrate kit SK-4100, Vector Laboratories). The 
reaction was stopped by rinsing in tap water and free-floating sections were stored in TBS. 
Sections were mounted onto object glasses (Superfrost Slides, Menzel, Braunschweig, Ger-
many). To dehydrate the tissue, object glasses were repetitively dipped into the organic xy-
lene-substitue NeoMount (Merck KGaA). Finally, they were coverslipped with the cover me-
dium NeoMount and a coverglass (24x60mm, Menzel). 
DNA-denaturation: As the two markers BrdU and PCNA are antigens located within the cell 
nucleus, additional steps had to be taken before the blocking step to break down the nuclear 
membrane and to make the DNA accessible by denaturation (Brown et al. 2003a): sections 
were incubated for 2h in 50% formamide (Merck KGaA) and 2x SSC (0.3M NaCl, 0.03M 
sodium citrate) at 65°C, followed by rinsing for 5min in 2x SSC at room temperature. Then, 
sections were incubated for 30min in 2M HCl at 37°C to denaturate DNA, and were rinsed for 
10min in 0.1M boric acid, pH 8.5, at room temperature. After several rinses in TBS, staining 
was continued with the blocking step. 
Antigen enhancements: For the mouse α-torsinA antibody, an antigen retrieval method had 
to be conducted to allow enhanced penetration (Shi et al. 1991; Gown et al. 1993). Before the 
hydrogen peroxide step, sections were mounted on gelatine coated object glasses (Engel-
brecht, Edemünde, Germany) and dried. An ascending alcohol row (20%, 50%, 70%, 95%, 
100%; 2min each) was performed for dehydration, slides were dried again and transferred into 
the antigen retrieval buffer (Citra Solution, BioGenex, San Ramon, CA, USA) diluted 1:10 in 
0.01M citrate buffer pH 6.0. In a microwave oven, the container was heated at 900W for 3min 
until it came to a rapid boil. After cooling down for 10min, another heating and a final cool 
down for 30min, a descending alcohol row was performed. Standard staining protocol was 
conducted with solutions pipetted directly onto the slides with sections surrounded by a oily 
line (Dako Pen, Dako, Glostrup, Denmark). 
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Prolongated incubation times: For the mouse α-V5 antibody, sufficient staining was 
achieved by extending incubation time of the primary antibody to 48h. 
Immunofluorescensce staining: For immunofluorescence stainings, the same protocol as in 
the immunoperoxidase stainings was conducted except for the hydrogen peroxide treatment. 
Two different antibodies were applied at the same time diluted in blocking buffer. After 48h 
of incubation and three washing steps in TBS, slides were incubated in the two respective 
secondary antibodies for another 12h: donkey α-mouse-IgG-488, donkey α-rat-IgG-568 or 
donkey α-goat-IgG-568 (all 1:1000, Molecular Probes, Eugene, OR, USA). Following steps 
were performed in the dark to avoid photobleaching. On the third day, sections were washed 
in TBS followed by 10min treatment with 0.5µM ToPro-3 (Molecular Probes) diluted in TBS 
to label nuclei. ToPro-3 is an intercalating agent that emits light at 661nm. Sections were 
mounted on object glasses (Superfrost Slides, Menzel) and coverslipped in Prolong Gold An-
tifade Reagent (Invitrogen, Eugene, OR, USA). 
 
4. Microscopy 
To evaluate the samples, different types of microscopes were used: Quantitative cell counting 
and volume analyses were performed at a Leica light microscope (Leica Microsystems 
GmbH) connected to a semiautomatic stereology system (Stereoinvestigator, MicroBright-
Field, Colchester, VT, USA) controlling the x- and y-stage position. 
For fluorescence microscopy, a confocal scanning laser microscope (Leica TCS-NT, Bens-
heim, Germany) was used. Laser light passing two confocally set pinholes excites one single 
focal point and therefore allows specific visualization of one z-layer. Probes are automatically 
line scanned to receive a complete picture of one layer in the z-plane. Sources of false-
positive signals in fluorescence microscopy include autofluorescence (from endogenous com-
ponents of the cells) and crosstalk (from simultaneous recording). Autofluorescence was ex-
cluded by the control stainings showing no positive signal. Crosstalk was observed as seen in 
Fig. 5; therefore, all confocal images were recorded sequentially (Pawley 2005). 
False-positive double labeling due to an overlay of signals from different cells was excluded 
by moving through the z-axis. Pictures were aquired in 1024x1024 pixels format with 8 aver-
aged shots on a 25x PL FLUOTAR oil objective (0.75 numerical aperture) or a 40x PL APO 
oil objective (1.25 numeric aperture). Pinhole setting was 105µm and corresponded to a focal 
plane of 2mm or less. 
A light microscope (Leica Microsystems GmbH, Wetzlar, Germany) equipped with 5x, 10x, 
20x, 40x and 100x objectives and a color video camera (Diagnostic Instruments, Sterling 
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Heights, MI, USA) was used for qualitative examinations of the DAB stainings via the con-
nected software (SPOT Advanced 3.5.4, Diagnostic Instruments, assembled by Visitron Sys-
tems GmbH, Puchheim, Germany). Illumation settings were adjusted to produce an image as 
close to the optical impression as possible. Gamma-correction was set to 0.8, noise filter to 
10% and chip defect correction to on. 
Anatomical regions were defined according to a reference atlas (Paxinos and Franklin 2004). 
All images were captured with each channel representing one fluorophore signal and were 
post-processed in Adobe Photoshop CS2 V9.0 (Adobe, San Jose, CA, USA). For pictures of 
the DAB stainings, the red color channel was converted into a black and white picture. If con-
trasts were too low, color levels were optimized without alienating the original image. 
 
5. Stereological Counting 
BrdU-positive cells were counted within the DG (including the SGZ) and the GCL and the 
GLOM. The researcher was blind to the genotype in order to avoid bias. For quantification of 
BrdU-labeled cells, design-based stereology was used which is a statistical method for esti-
mating total cell numbers within a three-dimensional structure. It is based on the evaluation of 
tissue sections of equal distance covering this structure. As every sixth section (with equal 
distance of 150µm) was evaluated, artifacts due to cutting-derived shrinkage of tissue are 
compensated. Cells intersecting the uppermost focal plane (exclusion plane) were not count-
ed. Total numbers of labeled cells as well as total volumes were obtained by multiplication 
with six (Schmitz and Hof 2005). Additionally, cell per volume (in µm³) densities were calcu-
 
Figure 5. Confocal laser scanning microscopy images with (A) simultaneous scanning in all three 
channels produces substantial crosstalk resulting in false-positive colocalization signal whereas 
sequential scanning (B) allows reliable separation of the signals. 
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lated by dividing total cell number by total volume. As both OB and hippocampus are located 
symmetrically within both hemispheres, total numbers given in this work must be doubled to 
obtain total numbers for both sides. 
The semi-automatic stereology system (Stereoinvestigator, MicroBrightField, Colchester, VT, 
USA) consisted of a light microscope with a black and white video camera and an automated 
stage control. Brain regions can be marked and measured on the screen. Also, the field of vi-
sion and the objective can be shifted without losing selections. First, reference volumes were 
determined by tracing the areas under the 20x objective. Total cell numbers in the DG and the 
GLOM were counted manually. The vast cell numbers in the GCL of the OB of one section 
were estimated with the optical fractionator method (West et al. 1991) using a virtual counting 
frame (Williams and Rakic 1988): the manually outlined GCL regions were overlaid by a grid 
and only parts, the counting frames, were quantified. Its left and bottom boundary were ex-
cluded (Fig. 6). Obtained counting numbers were multiplied with the reciprocal value of the 
sampling probability, i.e. the proportion of the counting frame area to one grid area. Counting 
frame size was 30x30µm² spaced in a grid size of 300x300µm² resulting in a ratio of one 
counted cell per 100 estimated cells of the GCL. PCNA-positive cells were manually counted 
in the SGZ / DG only as no differences were expected for the SVZ due to the equal numbers 
of BrdU-positive cells in all groups (see results). 
 
6. Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM) which reflects accuracy of 
the mean. As three different unmatched groups were to be compared, statistical analysis for 
the BrdU- and PCNA-positive cell numbers was performed using the one-way analysis of 
variance (ANOVA) which detects differences in the means of the groups using Prism 
(GraphPad Software Inc., San Diego, CA, USA). As a post-test, Tukey test was conducted to 
compare all pairs of groups. Significance level was set at p < 0.05. 
 
Figure 6. In the optical fractionator counting method, the anatomical region is first outlined (yel-
low) and then overlaid by a 300x300µm² grid (grey lines). Into each rectangle, a counting frame of 
30x30µm² is spaced bordered by two exclusion lines (red) and two inclusion lines (green). 
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D. Results 
1. Expression of transgenic and endogenous torsinA 
V5-antibody detected transgenic torsinA in both experimental groups hWT and hMT. In 
hWT, immunoreactivity for transgenic human wildtype torsinA was found throughout the 
mouse brain. All positive cells showed a cytoplasmatic signal and no staining of the nucleus. 
There was a range from weakly positive to strongly positive cells. Staining was most intense 
in the hindbrain and the cerebellum (Fig. 7A). In the hindbrain, several nuclei contained V5-
positive cells including the gigantocellular reticular nucleus (Fig. 7B), vestibular nuclei (Fig. 
7C) and pontine nuclei. At highest magnification, inclusion-like bodies were detectable (Fig. 
7D, E). Most positive cells within the brainstem had processes and a neuron-like shape. In the 
cerebellum, cells of the stratum granulosum without processes were strongly positive whereas 
almost no positive cells were seen in the Purkinje cell layer and the molecular layer (Fig. 7F). 
No positive cells were detected in the midbrain (substantia nigra, inferior and superior collicu-
lus). The hippocampus sparsely contained positive cells in the stratum granulosum of CA1 to 
CA3 – but not in the DG – all of them with branches reaching into the stratum moleculare 
(Fig. 7G). In the thalamus, sporadic cells were seen in the corresponding nuclei. The striatum 
did not contain any positive cells (Fig. 7H). Throughout the cortices of hWT animals, some 
pyramidal cells were positive for the transgene, with an increasing number from rostral to 
caudal: in the motor cortex, positive cells were rare whereas they were frequently detectable 
in cortical visual areas and the piriform cortex (Fig. 7I, J). These cortical V5-positive cells 
were all located in layers 4 and 5 and most of them had a shape similar to pyramidal cells due 
to their triangular soma and one main apical dendrite. In the OB, V5-expressing cells were 
found on the outside border of the GCL. All positive cells within that layer were aligned with 
a polarity between the GLOM on the basal side and the GCL on the apical side. Several pro-
cesses per cell were found directed towards the GLOM. They were not straightened perpen-
dicularly towards the pial surface, but rather interweavedly going into diverse directions (Fig. 
7K-M). Also, their neuron-like square somata exhibited dendritical connections between each 
other (Fig. 7N). No axonal or dendritical processes directed towards the GCL could be found. 
Similar to the hindbrain, inclusion-like bodies could be seen at highest magnification (Fig. 
7O). Throughout the GCL, some V5-positive cells without processes were observed wide-
spread in a low density without gathering. In summary, most prominent expression of the hu-
man wildtype transgene was detected in the brainstem and the cerebellum. Regarding the neu-
rogenic regions, high expression was found in the OB only. 
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In hMT animals overexpressing human mu-
tant torsinA, expression was much lower 
compared to hWT mice – V5-positive cells 
could be detected in a few distinct brain are-
as only when using an elongated incubation 
time of primary antibody (see methods chap-
ter). Similar to hWT animals, expression 
could also be demonstrated in the brainstem 
and in the cerebellum. In the brainstem, 
clusters of positive cells were found in the 
pontine nuclei exhibiting inclusion-like bod-
ies (Fig. 8A, B). In addition, positive cells 
were present in the cerebellar Purkinje layer 
(Fig. 8C) and in the mesencephalic subtha-
lamic nucleus (Fig. 8D). In all other areas including cortex, hippocampus and OB, no positive 
signal could be obtained. Altogether, in hMT animals, human mutant transgene staining was 
relatively low and detected mainly in brainstem, cerebellum and mesencephalon, but not in 
relation to the neurogenic zones.  
In summary, V5-antibody revealed high expression in brains of hWT animals, low expression 
in brains of hMT animals and no expression in the transgene-negative control group (negative 
control). This is consistent with the reported levels of expression in those lines: in hMT 
brains, twofold expression of transgenic human mutant torsinA compared to endogenous tor-
sinA had been measured on the protein level whereas in hWT brains, protein levels of the 
transgene had been sixfold compared to endogenous protein levels of torsinA (Grundmann et 
al. 2007). 
Anti-torsinA antibody D-M2A8 was used to detect endogenous torsinA. It has also been re-
ported to label both human mutant and human wildtype TorsinA in vitro (Hewett et al. 2003; 
Hewett et al. 2006) and in vivo, but not TorsinB (Hewett et al. 2004). In control animals, this 
 
Figure 7 (previous page). Summary of the detection sites of human wildtype torsinA in hWT mice: 
(A) Hindbrain and cerebellum showed most prominent staining, e.g. in the gigantocellular reticular 
nucleus (B) and the vestibular nucleus (C) where some of the positive cells also showed perinuclear 
inclu-sion-like bodies (D and E, respectively). In the cerebellum, cells of the stratum granulosum 
primarily showed the transgene (F). In the hippocampus, few cells of the CA1 region were found 
positive (G), whereas transgene was not detected in the striatum (H). Cortical layers 4 and 5 con-
tained positive cells, few in frontal areas like the motor cortex region (I) and more in caudal areas like 
the retrosplenial cortex (J). In the olfactory bulb, positive cells surrounded the granular cell layer, 
extending dendrites towards the glomerular cell layer (K - N). Here also, inclusion-like bodies were 
observed (O). Bars represent 50µm except for A, K and L (1mm). 
 
Figure 8. Detection of human mutant torsinA in 
hMT mice. Pontine reticular nucleus (A) con-
tained many immunoreactive cells with some of 
them showing perinuclear inclusions (B). Cerebel-
lar Purkinje cells (C) were also positive as well as 
cells of the subthalamic nucleus (D). Scale bars: 
50µm. 
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antibody shows the presence of endogenous torsinA. Weak immunoreactivity was found in 
neurons all over the mouse brain, staining the cytoplasm and the processes except for the nu-
clei (Fig. 9A). In hWT animals, where this antibody also recognizes transgenic protein in ad-
dition to endogenous torsinA, the distribution appeared to be more intense and more neurons 
were stained. Presence of the transgene within the OB surrounding the GCL could be demon-
strated (Fig. 9B). In hMT animals, torsinA signal had a medium intensity and the same distri-
bution as in control animals – here, the transgene could probably not be clearly stained due to 
its relatively low expression. 
In summary, localization of both endogenous torsinA and transgenic human wildtype or 
transgenic human mutant torsinA was confirmed by DAB-immunoperoxidase stainings as 
previously reported (Fig. 10). Despite of its limited functionality, anti-torsinA antibody con-
firmed that overall torsinA levels are higher in the transgenic animal lines compared to con-
trol animals which show a normal distribution of torsinA within the mouse brain. 
 
Figure 9. Antibody D-M2A8 detects both endogenous and transgenic torsinA. Despite high 
antibody titers and tissue pretreatments, signals were low in all lines. (A) TorsinA-positive cell 
detected in the brainstem of a control mouse. (B) Some torsinA-positive cells surrounding the 
granular cell layer of the olfactory bulb similar as in Fig. 7N. Scale bars: 50µm. 
 
Figure 10. Western blot analyses conducted by Grundmann et al. (2007). (A) While in control ani-
mals, only endogenous torsinA is present (37 kDa), D-M2A8 antibody also detects the transgene 
(40.7 kDa) in the transgenic lines – at low levels in hMT and at higher levels in hWT. (B) V5-
antibody specifically recognizing the transgene confirms a relatively high expression level in hWT 
as compared to hMT. (C) In homogenates of different brain regions of hWT mice, high transgene 
expression is present in cerebellum, brainstem, cortex and the OB (compare Fig. 7). 
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2. No colocalization of transgene and neuroblasts 
In order to further approach the influence of transgenic human mutant and human wildtype 
torsinA on adult neurogenesis of the experimental mice, confocal laser scanning microscopy 
was used to evaluate colocalization of the transgene (identified by the V5-tag) and DCX-
expressing cells (neuroblasts). In the control group animals, V5-antigen was not detected. 
DCX immunoreactivity was similar to previous reports in all groups (Brown et al. 2003b; 
Winner et al. 2004): In the hippocampus, DCX-positive cells were localized in the SGZ of the 
DG (Fig. 11A). Different morphological appearances of early and mature DCX-positive cells 
could also be distinguished. Early DCX-positive cells are located in the subgranular zone in 
clusters and have short processes parallel to the granule cell layer. Mature DCX-positive cells 
are characterized by localization within the granule cell layer and by long processes oriented 
towards or into the molecular layer. Also in the SVZ/OB neurogenic regions, DCX cells were 
similar to controls. In the SVZ, DCX-expressing cells had a round cell body with two or no 
processes and were lying close next to each other. In the RMS, their shape was elongated with 
long processes forming chain-like structures typically for migratory neuroblasts (Fig. 11B). In 
the OB, cells in the GCL extended neurites towards the mitral and glomerular cell layers (Fig. 
11C) and cells within the GLOM had processes between the glomeruli (Fig. 11D). Additional-
ly, few DCX-positive cells were localized in the striatum (see below).
 
In hWT animals, V5-immunoreactivity was found in accordance with the distribution in the 
DAB-stainings: Brainstem (Fig. 12A, B) and cerebellum (Fig. 12C) showed many V5-
positive cells; single positive cells were found in the hippocampal CA1 region (Fig. 12D) and 
in the cortex. Besides, perigranular expression of the transgene was confirmed in the OB. In 
the hippocampus, V5-immunoreactive cells of the CA1 had no visible contact with DCX-
positive cells. In the SVZ and RMS, no colocalization was found due to the absence of V5-
positive cells. In the GCL of the OB, V5-positive cells were sometimes found in proximity to 
the cell bodies of DCX-positive cells of the GCL. Additionally, an abundance of DCX-
 
Figure 11. In control mice, DCX immunoreactivity occured in the dentate gyrus of the hippocam-
pus (A), in the subventricular zone and the rostral migratory stream (B) and in the granular cell 
layer (C) and the glomerular cell layer (D) of the olfactory bulb. No differences were seen between 
controls and the two experimental groups. Scale bars: 100µm. 
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positive processes reaching towards the GLOM crossed the layer of V5-positive cells. How-
ever, no colocalization of V5 and DCX was found (Fig. 13). 
 
 
In hMT animals, V5 transgene was not detected within the neurogenic regions as found in the 
DAB-sections, thus, no colocalization could be demonstrated. 
In summary, the distribution of DCX expressing cells was similar in all groups and no colo-
calization of the DYT1 transgene and DCX could be found in the two transgenic groups. The 
only site where transgene and DCX-positive cells were in close proximity was the GCL of 
hWT animals. 
 
 
Figure 12. Immunofluorescence of the transgene in hWT animals was consistent with DAB 
stainings, e.g. in pontine nuclei (A), vestibular nucleus (B), cerebellar granule cell layer (C) and 
CA1 region of the hippocampus (D). Scale bars: 100µm. 
 
 
 
Figure 13. Colocalization studies revealing no coexpression of transgene and the early neuronal 
marker DCX in hWT mice. (A) Transgene-expressing cells around the granule cell layer of the 
olfactory bulb detected by V5-antibody do not colocalize with doublecortin (DCX), but are en-
closed by doublecortin-positive processes. (B) In the glomerular cell layer (left half of pictures), 
doublecortin-positive fibers crossing the transgene-positive cells ended within the glomeruli. Scale 
bars: 100µm. 
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3. Normal patterns of BrdU, PCNA and DCX in brains of trans-
genic animals 
To label newly generated cells, animals aged 5 months received daily injections of BrdU for 4 
days and were sacrifized 28 days later. In all groups, BrdU immunoreactivity was predomi-
nantly found in the GCL of the OB, in the DG of the hippocampus (Fig. 14A-C) and in the 
SVZ and RMS. Besides, BrdU-positive cells were found at low density all over the brain, 
representing glial or endothelial cells that have undergone cell division. 
 
PCNA is expressed in early G1- and in the S-phase of the cell cycle and used to determine the 
rate of cell proliferation within the neurogenic zones (Hall et al. 1990). PCNA staining pat-
terns were similar in all groups. High immunoreacitivity was found in the neurogenic zones. 
Positive cells were located at lower density along the RMS and at its entry into the GCL. Be-
sides, some PCNA-positive cells were dispersed all over the brain. 
In one animal of the hMT group, numbers of BrdU-positive cells were severalfold increased, 
especially in the cortical areas and the hippocampus (Fig. 14D-F). Hippocampal cell numbers 
of this animal exceeded the mean cell count of the other animals of this group by 39 standard 
deviations whereas olfactory bulb counts were within the 95% confidence intervals. Repeated 
immunostaining obtained the same results. Therefore, we hypothesized pathological changes 
in the brain of this animal, e.g. epileptic seizures (Parent et al. 1997; Couillard-Despres et al. 
2005) and excluded it from further analyses. 
No abnormal migration of DCX-positive cells: For the investigation of the striatum, the dis-
tribution of striatal DCX-immunoreactivity was analyzed in sagittal and coronal sections. In 
all groups, DCX-labeled cells were rarely found at a maximum of 3 cells per section, mostly 
 
Figure 14. BrdU staining of the dentate gyrus reveals no differences between (A) control, (B) 
hWT and (C) hMT animals. One animal of the hMT group was excluded from analyses because of 
abnormally increased and abnormally located BrdU-labeled cells in the dentate gyrus (D) and the 
cortex (E) when compared to controls (F). Scale bar = 50µm. 
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close to the SVZ (Fig. 15A,B). All cells had a mature appearance with one or more processes 
extended into different directions. 
Moreover, we quantified striatal BrdU-positive cells (with the following borders: lateral ven-
tricle caudally, corpus callosum dorso-rostrally and a sagittal straight line through the anterior 
commissure ventrally) in order to detect proliferative changes. No change was found between 
the three groups (Fig. 15C). 
 
4. Unchanged proliferation, survival and differentiation of adult 
newborn neurons in both transgenic groups 
Unchanged hippocampal proliferation and survival: PCNA- and BrdU-positive cells were 
counted to compare cell proliferation and survival of the newborn cells, respectively, between 
the three groups (Table 6). Estimated volumes were compared to check if the transgene had 
any morphological impact on the dentate gyrus. The mean estimated volume of the dentate 
gyrus was 0.10mm³ in all groups without significant differences (Fig. 16A). Statistical analy-
sis of the number of BrdU-positive cells in the dentate gyrus showed no significant difference 
between the groups (Fig. 16B). There was also no difference in PCNA cell counts (Fig. 16C). 
This means that none of the two transgenes has an influence on adult hippocampal neurogene-
sis, neither on cell proliferation nor on cell survival. 
 
 
Figure 15. Doublecortin-positive cells of the striatum were mostly found near the subventricular 
zone (A), rarely in more rostral parts (B) with no obvious differences between groups. The number 
of striatal BrdU-positive cells did not differ between groups (C). LV lateral ventricle. Scale bar = 
100µm. 
C 
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Region control hWT hMT 
Dentate gyrus    
   Volume (µm³) 0.1022 ± 0.002894 0.1061 ± 0.004004 0.1011 ± 0.002594 
   BrdU-positive cells 514.5 ± 67.41 593.1 ± 66.69 551.1 ± 22.39 
   PCNA-positive cells 634.5 ± 127.1 535.7 ± 59.23 570.9 ± 68.38 
Granular cell layer (OB)    
   Volume (µm³) 1.545 ± 0.08600 1.517 ± 0.05201 1.531 ± 0.04356 
   BrdU-positive cells 46500 ± 2689 49710 ± 4162 52030 ± 3958 
   Ratio NeuN+/BrdU+ cells 0.8538 ± 0.04589 0.8045 ± 0.00990 0.8908 ± 0.01902 
   Newborn neurons 39970 ± 4078 40160 ± 3696 43720 ± 2454 
Glomerular cell layer (OB)    
   Volume (µm³) 0.5820 ± 0.05155 0.5757 ± 0.08131 0.6240 ± 0.05153 
   BrdU-positive cells 3979 ± 415.7 3585 ± 562.3 3979 ± 415.7 
Table6. Stereological quantification of neurogenesis.in the animal models. Values are indicated ± standard error 
of the mean. There were no significant differences between groups. 
 
 
Figure 16. Stereological quantifications. Both transgenic lines did not differ from controls regard-
ing (A) volumes, (B) numbers of BrdU-positive cells and (C) numbers of PCNA-positive cells in 
the dentate gyrus and the granular and glomerular cell layer of the olfactory bulb. (D) There was 
also no difference in newborn neurons of the GCL. 
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Unchanged olfactory bulb neurogenesis: In the OB, comparison of the underlying volumes 
of the GCL and the GLOM revealed no difference (Table 6, Fig. 16A). Again, no influence of 
the transgene on the number of BrdU-labeled cells was detected, neither for the GCL nor for 
the GLOM (Fig. 9B). With no difference in the numbers of BrdU-positive cells of the OB 
given, we proceeded without analyzing PCNA in the SVZ/OB because altered proliferation 
would be expected cause altered survival counts. Even if there was altered proliferation, a 
functional impact would be unlikely due to unchanged survival. In order to ultimately exclude 
differences in the generation of newborn neurons, we analyzed differentiation of BrdU-
positive cells in the GCL by colocalization with the mature neuronal marker NeuN. Ratios of 
neuronal differentiation did not differ between groups (Table 6) and resulting estimated num-
bers of newborn neurons also showed no change (Table 6, Fig. 16D). 
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E. Discussion 
In the present study, the effect of overexpression of human wildtype and human mutant tor-
sinA on adult neurogenesis was examined in two transgenic mouse models. Partial presence 
of the transgenes within the neurogenic zones was shown, but no localization within neuro-
blasts could be found. Quantitative analyses of BrdU and PCNA immunohistochemistry re-
vealed no difference between transgenic and control groups concerning the number of newly 
generated cells and newborn neurons. This indicates that human wildtype and human mutant 
torsinA do no alter adult neurogenesis in these models of DYT1 primary torsion dystonia. 
 
1. Methods to quantify adult neurogenesis 
Our results of adult neurogenesis in the two transgenic mouse models are based on the use of 
established methods to determine adult neurogenesis in rodents. 
 
Antibodies: The antibodies used for immunohistochemistry (directed against torsinA, V5-tag 
and DCX) have all been characterized and are specific for their antigens. The DCX-antibody 
revealed a normal staining pattern. Both antibodies against torsinA and V5-tag only recog-
nized the antigen when using antigen enhancement methods. We could show endogenous and 
transgenic torsinA in different brain regions. TorsinA protein revealed by anti-torsinA anti-
body was present in neurons all over the brains of control mice. Staining was more intense in 
the high expressing hWT line and intermediate in the low expressing hMT line. V5-tagged 
transgenic torsinA could be detected in all areas described by Grundmann et al. (2007) except 
for the striatum. Therefore, tissue preparation methods might have reduced the sensitivity of 
the torsinA and V5-tag antibodies. 
 
BrdU labeling: Out of the number of neuroblasts that are generated during the 4 days of BrdU 
injection, only a limited amount will survive as a new part of the neurogenic target region. All 
other newly generated cells die during the first 4 weeks after BrdU injection (Kempermann et 
al. 2003). Thereafter, the rate of BrdU-labeled neurons remains basically unchanged at least 
for 1.5 years as it has been shown for the rat OB and the mouse hippocampus (Winner et al. 
2002; Kempermann et al. 2003). Consequently, neurons in our study that were BrdU-labeled 
28 days after the infusion are most probably integrated and mostly represent new neurons 
within the neurogenic destination zones. Recent reports found that neural stem cells retain the 
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same strands of DNA during all divisions [immortal strand hypothesis (Karpowicz et al. 
2005)]. Therefore, BrdU might not label the whole population of cycling stem cells, but will 
label deriving precursor cells and neuroblasts. As BrdU has been characterized intensively 
regarding its use in adult neurogenesis research, the injection paradigm that we used is a valid 
tool to determine the rate of survival of new neurons in the neurogenic zones. 
 
2. Conclusions for the pathophysiology of the mouse models 
No cell-autonomous effects of transgenic torsinA on neural precursors: As first aim, we 
investigated expression patterns of the transgenes. In both transgenic lines, transgenic torsinA 
was not expressed in neuroblasts of the adult brain, neither within the SGZ or the DG nor 
within the SVZ or the OB. As the transgenes were not present in any cells of the two niches of 
active adult neural stem cells (SVZ and SGZ), we infer that they are also not expressed in 
neural stem cells. In the OB of the hWT group, cells at the outer margin of the GCL were pos-
itive for the hWT torsinA. These cells were most likely mitral cells because they had primary 
dendrites directed into the GLOM and secondary dendrites to other cells of this layer. Accord-
ingly, no colocalization was found with the neuroblast marker DCX, and DCX-positive pro-
cesses of immature granule cells were in contact with the transgene-expressing cells. As the 
transgenes are not expressed in neural stem cells, neuroblasts or newly generated mature neu-
rons, they are unlikely to exert cell-autonomous effects on adult neurogenesis in both animal 
models. We therefore speculate that potential interactions between torsinA and adult neuro-
genesis are cell non-autonomous. 
 
No migration of newborn neurons into the striatum: We also suspected that the migration of 
newborn cells could be redirected in transgenic mice. We examined the caudate putamen part 
of the striatum particularly carefully for presence of DCX- and BrdU-labeled cells because the 
striatum of hWT animals had been shown to be affected by the transgene in matters of neuro-
pathology, white matter circuit changes, behavioral phenotype and metabolism of dopamine 
and serotonine (Grundmann et al. 2007). Besides, abnormally localized DCX-positive cells in 
the striatum were speculated in advance (Grundmann, personal communication). 
The observation that some DCX-positive cells are also found in the striatum is not a new one. 
Rather than being neuroblasts, these striatal DCX-positive cells have been associated – in 
non-pathologic wildtype animals – with non-migrating neurons undergoing plasticity in form 
of synaptic reorganization (Nacher et al. 2001). 
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hMT animals do not show neurochemical changes in the striatum, but striatal dopamine and 
serotonin levels are decreased in hWT animals (Grundmann et al. 2007). Experimental striatal 
dopamine-depletion by 6-OHDA lesion does not lead to increased striatal DCX-positive cells 
(Winner et al. 2008a). Importantly, striatal DCX expression and striatal BrdU incorporation 
did not vary between groups excluding a redirected migration of neuroblasts into the SVZ-
adjacent striatum. This means also that we could not find signs of enhanced striatal plasticity 
reflected by increased DCX expression. Also in other motor regions of the brain, patterns of 
BrdU, PCNA and DCX immunoreactivity did not differ from controls. In particular, no exces-
sive cell numbers were found in motor cortex, SNc and cerebellum. We conclude that altered 
plasticity in the basal ganglia circuits of DYT1 mice is not due to the integration of new neu-
rons. 
 
Aggregation per se does not decrease adult neurogenesis: As we found torsinA-related in-
clusion bodies in mitral cells of the OB in close relation to the GCL and the GLOM, we ex-
pected an effect of torsinA at the integration site of newborn granule cells. Against our own 
anticipation, torsinA-related inclusions, however, did not affect the survival of newly born 
cells despite its accumulation in the local microenvironment. In the mouse model of 
Marxreiter et al. (2009), transgenic human α-synuclein was overexpressed in mature granule 
cells of the OB. In this model, inclusions led to increased cell death of newly generated neu-
rons. Therefore, we hypothesize that α-synuclein expression in newborn neurons may lead to 
cell-autonomous effects at their integration site. The lack of torsinA-associated cell-non-
autonomous effects may due to its lack of expression within mature newborn neurons com-
pared with α-synuclein. 
 
Influence of altered neurotransmitter levels: The fact that we could not detect an influence 
of the transgenes on adult neurogenesis is also surprising since both transgenic groups show 
alterations of neurotransmitters that have been reported to modulate adult neurogenesis.  
Striatal dopamine and serotonin levels in hWT animals are significantly decreased as well as 
the dopamine metabolite HVA within the brainstem. Accordingly, hWT animals show a hy-
poactive phenotype in behavioral tests (Grundmann et al. 2007). In hMT animals, the dopa-
mine metabolite DOPAC as well as serotonin and its metabolite 5-HIAA were increased in 
the brainstem. Possibly as a consequence of increased serotonin, they were hyperactive 
(Grundmann et al. 2007). In the majority of other murine animal models of DYT1 dystonia 
published so far, levels of striatal dopamine and its metabolites were also altered (Dang et al. 
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2005; Sharma et al. 2005; Shashidharan et al. 2005; Dang et al. 2006; Balcioglu et al. 2007; 
Zhao et al. 2008b). Both dopamine and serotonin have repeatedly been shown to promote 
adult neurogenesis (Baker et al. 2004; Banasr et al. 2004; Hoglinger et al. 2004; Winner et al. 
2006). Changes in proliferation and survival are revealed most easily in young animals at the 
age of about 2 months due to the age-dependent decline of adult neurogenesis (Kuhn et al. 
1996; Tropepe et al. 1997). Nevertheless, we chose 5 months old animals for our analyses 
because in both lines, behavioral and neurochemical changes could only be detected from this 
age on (Grundmann et al. 2007) which may have obscured minor changes of adult neurogene-
sis. Therefore, the relatively small changes in transmitter levels (that did not exceed 25%) 
probably were not effective enough to produce a detectable change of adult neurogenesis 
(Wichmann 2008). Decreased striatal dopamine levels could also have compensated the ef-
fects of increased serotonin levels. 
Two other features of the mouse models (neuropathological inclusions and altered white mat-
ter connectivity) occurred independent of the age of the transgenic animals. Therefore, an 
effect of these on adult neurogenesis is unlikely. 
 
3. The DYT1 mouse model of dystonia 
To be able to confer findings in animal models to the human disease, it is important to note 
that animals bear important differences in lifespan, physiology and disease etiology. In animal 
models, one or few cardinal features of the human disorder are replicated, but it is rarely pos-
sible to produce an identical phenotype. Rodent animal models are widely used in research 
because they are also mammalian, they show a comparable anatomy, are easy to handle, can 
be modified genetically and have a relatively short reproductive cycle period. However, their 
limited lifespan makes it difficult to model chronic diseases of the CNS that develop over 
several years. 
 
Comparison to other DYT1 models: In the knock-in, knock-down and knock-out dystonia 
mouse models, histological results predominated the phenotype (Dang et al. 2005; Goodchild 
et al. 2005; Dang et al. 2006). Models transgenic for human mutant torsinA in addition exhib-
ited behavioral and neurochemical alterations in dopamine metabolism (Shashidharan et al. 
2005; Pisani et al. 2006; Balcioglu et al. 2007; Grundmann et al. 2007; Zhao et al. 2008b). 
Individual results concerning behavioral alterations and neurochemical changes differ be-
tween different DYT1 transgenic models. Differences in genetic background, constructs used 
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for transfection and age at the time of analysis have been discussed as possible reasons for 
inhomogeneities between the models (Wichmann 2008; Zhao et al. 2008b). 
For example, Shashidharan et al. (2005) observed a dystonic movement phenotype in 40% of 
all transgenic mice. This limited penetrance unlikely corresponds to the 30% penetrance of 
DYT1 in humans, but rather resulted from insufficient genetic uniformity since the authors 
investigated F1 offspring only. In all the other models, reduced penetrance of the phenotypes 
could not be replicated, possibly because the putative second hit (environmental or genetic) is 
missing that human mutation carriers need in order to develop symptoms. 
We assume that the two models used in our study are appropriate because they are derived 
from a cause known to cause PTD in humans (etiologic validity) and because they deliver 
reproducible results that are partially in line with earlier models (reliability). However, no 
obvious motor syndrome of involuntary muscle contractions is present in the animals (Jinnah 
et al. 2005). 
 
Time of investigation: In human carriers of the DYT1 mutation, PTD has an onset between 
the age of 5 to 25 years in one third of all cases while the remaining two thirds are unaffected 
throughout life. Compared to classical neurodegenerative disorders, this is early, but it might 
be too late compared to the 2 to 3 years lifespan of a laboratory mouse. Therefore, the effects 
of the genetic modification are often multiplied by expression of a transgene under a strong 
promoter. Consistently, the alterations in DYT1 knock-in, knock-down and knock-out mice 
are less pronounced than in the available transgenic DYT1 models. 
 
Spatial expression pattern of the transgenes: Endogenous torsinA protein is expressed weak-
ly in cells of all grey matter regions and highly in SNc, cerebellum and striatum 
(Shashidharan et al. 2000; Konakova et al. 2001; Konakova and Pulst 2001; Augood et al. 
2003). In the CNS, the murine prion protein promoter drives mRNA expression in neurons of 
all brain areas and to a lower extent in glial cells (Kretzschmar et al. 1986; Moser et al. 1995; 
Borchelt et al. 1996). Endogenous mouse prion protein was found ubiquitously in all subpop-
ulations of neurons and some glial cells (Laine et al. 2001). Others reported it to be restricted 
to GABAergic neurons of the cortex and the cerebellum only, highlighting the important role 
of transcriptional, post-transcriptional and post-translational regulation of the prp-protein 
(Ford et al. 2002). In a study that expressed α-synuclein under control of the murine prp-
promoter, CNS protein expression was most abundant in cortex, hippocampus, colliculi and 
cerebellum (Maskri et al. 2004). In our study, however, expression occurred strongest in areas 
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of the brainstem and the cerebellum. This difference might be attributed to the different 
lengths of the prp-promoters that were used as the mouse prion protein exhibits promoter ac-
tivity at least up to exon 2 (Baybutt and Manson 1997). Expression or overexpression of tor-
sinA might also be impaired in some brain areas due to post-transcriptional regulations like 
low translation efficiency, impaired protein trafficking or short half-life of the transgene. A 
possible reason for the disparity of distributions of endogenous and transgenic torsinA in our 
study could be the fact that human and not mouse torsinA was used as transgene and is there-
fore processed differently. Moreover, the V5-tag of the transgenes can also influence tran-
scription or stability of the construct. The immunohistochemical localization of transgenic 
human torsinA in turn was similar to that observed in the transgenic mice by Shashidharan et 
al. (2005) who also expressed human mutant torsinA, but under the control of the neuronal 
NSE-promoter. In both of these models, intracellular aggregations were found in nuclei of the 
brainstem. Similar inclusion bodies were reported in human PTD patients, also restricted to 
their brainstems (McNaught et al. 2004). In summary, the expression pattern of transgenic 
torsinA in the mouse models that we used is consistent with another mouse model. In addi-
tion, the promoter is able to replicate the brainstem morphology of PTD patients. 
 
Temporal expression patterns of the transgenes: As torsinA is thought to exert its functions 
predominantly during neural development, it is important to evaluate how expression patterns 
of endogenous and transgenic torsinA overlap temporally. 
A study in humans showed that the expression of human endogenous torsinA starts within 
most brain regions at the postnatal age of 4 weeks with an abrupt onset; it is most prominently 
expressed around 6 weeks of age and declines down during childhood to a supposedly life-
long plateau of expression (Siegert et al. 2005). Hence, the time of peak expression does not 
overlap with the morphological development of brain structures, but it is paralleled by the 
period of synaptogenesis, synaptic remodeling and process elimination. In accordance with 
the developmental expression of torsinA in humans, mouse and rat torsinA expression peaks 
from embryonic day 15 to postnatal day 14 (Xiao et al. 2004; Vasudevan et al. 2006). 
In contrast, mouse prp-promoter is not active in embryonic neuronal precursor cells of mice, 
but is upregulated in neurons upon complete differentiation (Tremblay et al. 2007). Another 
study showed that in adult mice, prion protein is expressed highly in mature neurons and also 
immediately adjacent to the SVZ, but not in mitotically active cells (Steele et al. 2006). 
This is compatible with our observation that neither of the transgenes was expressed in neural 
precursor cells or neuroblasts. Consequently, we assume that there is a mismatch between 
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endogenous and transgenic torsinA expression concerning their developmental expression 
patterns: endogenous torsinA appears early during neuronal migration and synaptogenesis and 
declines thereafter whereas the prp-promoter is specifically active in differentiated neurons 
and maintains high expression throughout life.  
Thus, our animal models might not have been able to reflect a cell-autonomous effect of 
DYT1 on adult neurogenesis. It has not been shown if endogenous torsinA is expressed in 
adult neural precursor cells because there are only studies about embryonic expression 
(Vasudevan et al. 2006). There are complex transitions between embryonic/perinatal and adult 
neurogenesis, so results from embryonic studies cannot be extrapolated to the adult situation 
(Altman and Bayer 1990; D'Amour and Gage 2003). Therefore, future studies should first 
characterize the expression of endogenous torsinA in adult neural stem and progenitor cells. 
 
Conclusions for adult neurogenesis in DYT1 patients: As demonstrated above, animal mod-
el in this study only partially reflects DYT1-related dystonia in humans. The model still pro-
vides a good means to investigate certain aspects of the disease. The transgenic models that 
we used replicate the findings of intraneuronal inclusion bodies in the brainstem of DYT1 
patients. Thus, we conclude that these inclusions likely do not affect adult neurogenesis. Be-
sides, there was no evidence for reactive alterations in adult neurogenesis due to basal ganglia 
pathology. 
 
4. Conclusions for primary dystonias in humans 
Subcellular forms of neuronal development and plasticity involved in dystonia: Neither he-
reditary nor sporadic forms of PTD show a phenotype from birth on, but have an onset during 
lifetime. Signs predicting if and at which time the disease will evolve are not known up to 
now (Bressman 2004). 
TorsinA, on the contrary, is thought to exert its functions predominantly during brain devel-
opment: Homozygous knock-out of wildtype torsinA results in a lethal phenotype (Goodchild 
et al. 2005). Besides, torsinA expression in rodents and humans is highest during the phases 
of cortical synaptogenesis, synaptic remodeling and process elimination (Xiao et al. 2004; 
Siegert et al. 2005; Vasudevan et al. 2006). In human cortical brain areas, this span extends 
from 6 to 16 years of age (Huttenlocher 1979; Huttenlocher 1990; Andersen 2003) coinciding 
with the temporal window of DYT1 PTD onset. Before the PTD onset, embryonic neurogene-
sis has ceased in most areas of the brain – consistent with the absence of gross morphological 
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abnormalities in DYT1 patients and dystonia patients in general. Therefore, it seems plausible 
that the pathophysiology of dystonias is due to abnormal connectivity between neurons rather 
than due to alterations in the embryonic generation of neurons. 
The development of sporadic, adult-onset primary dystonias, especially task-specific dystoni-
as like writer’s cramp, has been related to excessive sensory stimulation or repetition of motor 
tasks (Quartarone et al. 2006). Intense training of motor skills during writing or when playing 
an instrument leads to somatotopic reorganization of activated sensorimotor areas both in cor-
tex and basal ganglia. This reorganization is thought to be mediated by synaptic changes re-
sulting in a decrease of inhibitory inputs to the affected motor areas (Watson 2006). 
 
Imbalances of striatal dopaminergic metabolism in dystonia and Parkinson’s: The role of 
striatal dopamine metabolism in the development of dystonias is supported by many findings. 
For instance, striatal dopamine metabolite levels are elevated in human tissue specimen of 
dystonia patients (Augood et al. 2002), nuclear imaging studies showed abnormal striatal do-
paminergic neurotransmission in dystonia patients (Perlmutter and Mink 2004) and dopamine 
receptor antagonists in schizophrenia may cause dystonic side-effects (Casey 2004). All 
transgenic animal models of dystonia where striatal transmitter levels have been analyzed 
show alterations of dopamine metabolism (Zhao et al. 2008b). In humans, gene mutations 
linked to dopaminergic neurotransmission, e.g. in the tyrosine hydroxylase gene or the dopa-
mine D2 receptor gene, cause genetic forms of dystonia (Klein and Ozelius 2002). In addition, 
the symptom dystonia is frequently found in PD patients, as a complication of long-term do-
paminergic treatment – known as “off-phase” dystonia – or as the initial symptom of the dis-
ease (Katzenschlager et al. 2002; Bruno et al. 2004; Ceballos-Baumann and Conrad 2005).  
Interestingly, dopamine modulates striatal synaptic plasticity in PD (Picconi et al. 2003). Plas-
ticity processes in humans can be examined by measuring the facilitation of motor cortex 
stimulation after stimulation of another cortical area or a peripheral nerve. In PD patients, 
these kinds of facilitation are effective only in the “on”-state which is characterized by high 
availability of dopamine, but not in the dopamine-lacking “off”-state (Mir et al. 2005; Ueki et 
al. 2006). This role of dopamine in modulating plasticity might also contribute to dystonia, 
and again, would not involve the generation of new neurons. 
Despite similarities between PD and dystonia, no degenerative indications of neuronal loss or 
inflammation are found in brains of dystonia patients whereas in PD, dopaminergic degenera-
tion in the SNc leads to motor dysfunction (Rostasy et al. 2003). In DYT1 dystonia, mutant 
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torsinA accumulates in the perinuclear space of neurons, but obviously is not as toxic as α-
synuclein in PD. 
Another important difference between PD and DYT1 dystonia is the extent of dopaminergic 
dysfunction. In PD, dopamine levels are substantially reduced whereas in dystonia, dopamine 
or its metabolites are only modestly affected (Wichmann 2008).  
 
Symptoms related to impaired neurogenesis:  In PD, HD and depression, impairments of 
adult neurogenesis could contribute to non-motor symptoms, particularly to the decline of 
hippocampus-dependent memory and to the loss of odor perception (Mirescu and Gould 
2006; Ross et al. 2008). Primary dystonia, in contrast, is a mere motor disease without pro-
nounced additional neurological or psychiatric abnormalities. Observed comorbidity of de-
pression in dystonia is most likely secondary rather than being causally related to the DYT1 
mutation (Heiman et al. 2004; Miller et al. 2007). 
 
Perspectives: To investigate the involvement of adult neurogenesis in DYT1 dystonia pa-
tients, the effect of DYT1 overexpression or knock-down in cultured neural precursor cells on 
proliferation and differentiation could be examined. In vivo, hippocampal and SVZ cell pro-
liferation of DYT1 brain specimen may be determined to show definite evidence of unaltered 
precursor proliferation in the patients. Since dystonia is related to changes in plasticity and 
neurons generated in adulthood provide a model to study the formation of new neuronal cir-
cuits, we also suggest to investigate qualitative integration of newborn neurons in the trans-
genic animals as measured by dendrite and spine numbers, for example. Finally, it would be 
feasible to treat transgenic animals with dopaminergic compounds in order to investigate ef-
fects on motor dysfunction and on adult neurogenesis. 
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F. Manuscript: Adult neural precursor cells unaffected in 
animal models of DYT1 dystonia (Neuroreport, 2009) 
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G. Appendix 
1. Abbreviations 
5-HIAA 5-Hydroxyindoleacetic acid 
6-OHDA 6-Hydroxydopamine 
AD Alzheimer’s disease 
BDNF Brain-derived neurotrophic factor 
BiP Immunoglobulin heavy chain-binding protein 
BrdU Bromodeoxyuridine 
CA3/CA1 Parts of the hippocampus (“cornu ammonis”) 
CMV Cytomegalovirus 
CNS Central nervous system 
DCX Doublecortin 
DG Dentate gyrus 
DOPAC Dihydroxyphenylacetic acid 
EGF Epidermal growth factor 
ER Endoplasmic reticulum 
FGF-2 Fibroblast growth factor 2 
GABA γ-aminobutyric acid 
GCL Granular cell layer of the olfactory bulb 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
GLOM Glomerular cell layer of the olfactory bulb 
HD Huntington’s disease 
HVA Homovanillic acid 
M Molar concentration (mol/L) 
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRI Magnetic resonance imaging 
NeuN Neuronal nuclei 
NSE Neuron-specific enolase 
OB Olfactory bulb 
PD Parkinson’s disease 
PET Positron emission tomography 
PSA-NCAM Polysialylated form of the neural cell adhesion molecule 
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PTD Primary torsion dystonia 
RMS Rostral migratory stream 
SGZ Subgranular zone of the dentate gyrus 
SNc Pars compacta of the substantia nigra 
SVZ Subventricular zone of the lateral ventricles 
TMS Transcranial magnetic stimulation 
VEGF Vascular endothelial growth factor 
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